- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
AstraZeneca Pharma India Limited — Important, 08-05-2025: General Updates
08-05-2025 | 01:29 pm
08-05-2025 | 01:29 pm
AstraZeneca Pharma India has announced a board meeting and received approval to import and market Trastuzumab deruxtecan (Enhertu®) for an expanded breast cancer indication. Enhertu can now be used as monotherapy for unresectable or metastatic HER2-low/ultralow breast cancer after prior endocrine therapy, strengthening AstraZeneca’s oncology portfolio and potentially enhancing future revenue.
No comments yet. Be the first to comment!